A guide to non-alcoholic fatty liver disease in childhood and adolescence

International Journal of Molecular Sciences

Volumn 17, Issue 6, 2016, Pages

  Temple, Jonathan L ^a   Cordero, Paul ^b   Li, Jiawei ^b   Nguyen, Vi ^b   Oben, Jude A ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adolescent; Children; NAFLD; Obesity; Steatosis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PIOGLITAZONE; URSODEOXYCHOLIC ACID;

ADOLESCENCE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DYSLIPIDEMIA; EXERCISE; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATIVE STRESS; PUBERTY; REVIEW; STEATOSIS; THYROTROPIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WESTERN DIET; ADOLESCENT; AGE; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE MANAGEMENT; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR;

ADOLESCENT; AGE FACTORS; CARCINOMA, HEPATOCELLULAR; CHILD; DISEASE MANAGEMENT; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84975037739     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17060947     Document Type: Review

References (190)

1. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221-1231. [CrossRef] [PubMed]
2. Lawlor, D.A.; Callaway, M.; Macdonald-Wallis, C.; Anderson, E.; Fraser, A.; Howe, L.D.; Day, C.; Sattar, N. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: A cross-sectional study of 1874 general population adolescents. J. Clin. Endocrinol. Metab. 2014, 99, E410-E417. [CrossRef] [PubMed]
3. Alexander, J.; Torbenson, M.; Wu, T.T.; Yeh, M.M. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study. J. Gastroenterol. Hepatol. 2013, 28, 848-854. [CrossRef] [PubMed]
4. Alisi, A.; Cianfarani, S.; Manco, M.; Agostoni, C.; Nobili, V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: Pathogenetic role of genetic background and intrauterine environment. Ann. Med. 2012, 44, 29-40. [CrossRef] [PubMed]
5. Perticone, M.; Cimellaro, A.; Maio, R.; Caroleo, B.; Sciacqua, A.; Sesti, G.; Perticone, F. Additive effect of non-alcoholic fatty liver disease on metabolic syndrome-related endothelial dysfunction in hypertensive patients. Int. J. Mol. Sci. 2016, 17. [CrossRef] [PubMed]
6. Ayonrinde, O.T.; Olynyk, J.K.; Marsh, J.A.; Beilin, L.J.; Mori, T.A.; Oddy, W.H.; Adams, L.A. Childhood adiposity trajectories and risk of nonalcoholic fatty liver disease in adolescents. J. Gastroenterol. Hepatol. 2015, 30, 163-171. [CrossRef] [PubMed]
7. Moran, J.R.; Ghishan, F.K.; Halter, S.A.; Greene, H.L. Steatohepatitis in obese children: A cause of chronic liver dysfunction. Am. J. Gastroenterol. 1983, 78, 374-377. [PubMed]
8. Marcason, W. What are the current guidelines for pediatric non-alcoholic fatty liver disease? J. Acad. Nutr. Diet. 2013, 113, 1772. [CrossRef] [PubMed]
9. Mencin, A.A.; Lavine, J.E. Advances in pediatric nonalcoholic fatty liver disease. Pediatr. Clin. N. Am. 2011, 58, 1375-1392. [CrossRef] [PubMed]
10. Monteiro, P.A.; Antunes Bde, M.; Silveira, L.S.; Christofaro, D.G.; Fernandes, R.A.; Freitas Junior, I.F. Body composition variables as predictors of nafld by ultrasound in obese children and adolescents. BMC Pediatr. 2014, 14, 25. [CrossRef] [PubMed]
11. Ratziu, V.; Bellentani, S.; Cortez-Pinto, H.; Day, C.; Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010, 53, 372-384. [CrossRef] [PubMed]
12. Berardis, S.; Sokal, E. Pediatric non-alcoholic fatty liver disease: An increasing public health issue. Eur. J. Pediatr. 2014, 173, 131-139. [CrossRef] [PubMed]
13. Schwimmer, J.B.; Deutsch, R.; Kahen, T.; Lavine, J.E.; Stanley, C.; Behling, C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118, 1388-1393. [CrossRef] [PubMed]
14. Holterman, A.; Gurria, J.; Tanpure, S.; DiSomma, N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Semin. Pediatr. Surg. 2014, 23, 49-57. [CrossRef] [PubMed]
15. Vajro, P.; Ferrante, L.; Lenta, S.; Mandato, C.; Persico, M. Management of adults with paediatric-onset chronic liver disease: Strategic issues for transition care. Dig. Liver Dis. 2014, 46, 295-301. [CrossRef] [PubMed]
16. Palmer, N.D.; Musani, S.K.; Yerges-Armstrong, L.M.; Feitosa, M.F.; Bielak, L.F.; Hernaez, R.; Kahali, B.; Carr, J.J.; Harris, T.B.; Jhun, M.A. et al. Characterization of european ancestry nonalcoholic fatty liver disease-associated variants in individuals of african and hispanic descent. Hepatology 2013, 58, 966-975. [CrossRef] [PubMed]
17. Vajro, P.; Lenta, S.; Socha, P.; Dhawan, A.; McKiernan, P.; Baumann, U.; Durmaz, O.; Lacaille, F.; McLin, V.; Nobili, V. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: Position paper of the espghan hepatology committee. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 700-713. [CrossRef] [PubMed]
18. Boyraz, M.; Hatipoglu, N.; Sari, E.; Akcay, A.; Taskin, N.; Ulucan, K.; Akcay, T. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes. Res. Clin. Pract. 2014, 8, e356-e363. [CrossRef] [PubMed]
19. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Diehl, A.M.; Brunt, E.M.; Cusi, K.; Charlton, M.; Sanyal, A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Am. J. Gastroenterol. 2012, 107, 811-826. [CrossRef] [PubMed]
20. Deng, J.; Fishbein, M.H.; Rigsby, C.K.; Zhang, G.; Schoeneman, S.E.; Donaldson, J.S. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr. Radiol. 2014, 44, 1379-1387. [CrossRef] [PubMed]
21. Liccardo, D.; Alisi, A.; Porta, G.; Nobili, V. Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review. Expert Rev. Gastroenterol. Hepatol. 2013, 7, 601-604. [CrossRef] [PubMed]
22. Lerret, S.M.; Garcia-Rodriguez, L.; Skelton, J.; Biank, V.; Kilway, D.; Telega, G. Predictors of nonalcoholic steatohepatitis in obese children. Gastroenterol. Nurs. 2011, 34, 434-437. [CrossRef] [PubMed]
23. Navarro-Jarabo, J.M.; Ubina-Aznar, E.; Tapia-Ceballos, L.; Ortiz-Cuevas, C.; Perez-Aisa, M.A.; Rivas-Ruiz, F.; Andrade, R.J.; Perea-Milla, E. Hepatic steatosis and severity-related factors in obese children. J. Gastroenterol. Hepatol. 2013, 28, 1532-1538. [CrossRef] [PubMed]
24. Alisi, A.; Nobili, V. Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. Nutrition 2012, 28, 722-726. [CrossRef] [PubMed]
25. Ozhan, B.; Ersoy, B.; Kiremitci, S.; Ozkol, M.; Taneli, F. Insulin sensitivity indices: Fasting versus glucose-stimulated indices in pediatric non-alcoholic fatty liver disease. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 3450-3458. [PubMed]
26. Anderson, E.L.; Howe, L.D.; Jones, H.E.; Higgins, J.P.; Lawlor, D.A.; Fraser, A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS ONE 2015, 10, e0140908. [CrossRef] [PubMed]
27. Kelsey, M.M.; Zaepfel, A.; Bjornstad, P.; Nadeau, K.J. Age-related consequences of childhood obesity. Gerontology 2014, 60, 222-228. [CrossRef] [PubMed]
28. Regnell, S.E.; Peterson, P.; Trinh, L.; Broberg, P.; Leander, P.; Lernmark, A.; Mansson, S.; Elding Larsson, H. Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls. Metabolism 2015, 64, 872-878. [CrossRef] [PubMed]
29. Mansoor, S.; Yerian, L.; Kohli, R.; Xanthakos, S.; Angulo, P.; Ling, S.; Lopez, R.; Christine, C.K.; Feldstein, A.E.; Alkhouri, N. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig. Dis. Sci. 2015, 60, 1440-1447. [CrossRef] [PubMed]
30. Trovato, F.M.; Martines, G.F.; Brischetto, D.; Catalano, D.; Musumeci, G.; Trovato, G.M. Fatty liver disease and lifestyle in youngsters: Diet, food intake frequency, exercise, sleep shortage and fashion. Liver Int. 2016, 36, 427-433. [CrossRef] [PubMed]
31. Younossi, Z.M.; Stepanova, M.; Negro, F.; Hallaji, S.; Younossi, Y.; Lam, B.; Srishord, M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012, 91, 319-327. [CrossRef] [PubMed]
32. Silveira, L.S.; Monteiro, P.A.; Antunes Bde, M.; Seraphim, P.M.; Fernandes, R.A.; Christofaro, D.G.; Freitas Junior, I.F. Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth. BMC Pediatr. 2013, 13, 115. [CrossRef] [PubMed]
33. Kelishadi, R.; Cook, S.R.; Adibi, A.; Faghihimani, Z.; Ghatrehsamani, S.; Beihaghi, A.; Salehi, H.; Khavarian, N.; Poursafa, P. Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol. Metab. Syndr. 2009, 1, 29. [CrossRef] [PubMed]
34. Manco, M.; Bedogni, G.; Marcellini, M.; Devito, R.; Ciampalini, P.; Sartorelli, M.R.; Comparcola, D.; Piemonte, F.; Nobili, V. Waist circumference correlates with liver fibrosis in children with non-alcoholic steatohepatitis. Gut 2008, 57, 1283-1287. [CrossRef] [PubMed]
35. Alterio, A.; Alisi, A.; Liccardo, D.; Nobili, V. Non-alcoholic fatty liver and metabolic syndrome in children: A vicious circle. Horm. Res. Paediatr. 2014, 82, 283-289. [CrossRef] [PubMed]
36. Mager, D.R.; Yap, J.; Rodriguez-Dimitrescu, C.; Mazurak, V.; Ball, G.; Gilmour, S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. Nutr. Clin. Pract. 2013, 28, 101-111. [CrossRef] [PubMed]
37. Boyraz, M.; Cekmez, F.; Karaoglu, A.; Cinaz, P.; Durak, M.; Bideci, A. Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark. Med. 2013, 7, 423-428. [CrossRef] [PubMed]
38. Sayin, O.; Tokgoz, Y.; Arslan, N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J. Pediatr. Endocrinol. Metab. 2014, 27, 479-484. [CrossRef] [PubMed]
39. Li, W.; Zheng, L.; Sheng, C.; Cheng, X.; Qing, L.; Qu, S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011, 10, 49. [CrossRef] [PubMed]
40. Adams, L.A.; Lymp, J.F.; St Sauver, J.; Sanderson, S.O.; Lindor, K.D.; Feldstein, A.; Angulo, P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005, 129, 113-121. [CrossRef] [PubMed]
41. Ekstedt, M.; Franzen, L.E.; Mathiesen, U.L.; Thorelius, L.; Holmqvist, M.; Bodemar, G.; Kechagias, S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865-873. [CrossRef] [PubMed]
42. Ong, J.P.; Pitts, A.; Younossi, Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol. 2008, 49, 608-612. [CrossRef] [PubMed]
43. Schwimmer, J.B.; Newton, K.P.; Awai, H.I.; Choi, L.J.; Garcia, M.A.; Ellis, L.L.; Vanderwall, K.; Fontanesi, J. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2013, 38, 1267-1277. [CrossRef] [PubMed]
44. Holterman, A.X.; Guzman, G.; Fantuzzi, G.; Wang, H.; Aigner, K.; Browne, A.; Holterman, M. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity 2013, 21, 591-597. [CrossRef] [PubMed]
45. Charlotte, F.; Le Naour, G.; Bernhardt, C.; Poynard, T.; Ratziu, V.; Group, L.S. A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. Hum. Pathol. 2010, 41, 1178-1185. [CrossRef] [PubMed]
46. Caldwell, S.H.; Crespo, D.M.; Kang, H.S.; Al-Osaimi, A.M. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127, S97-S103. [CrossRef] [PubMed]
47. El-Serag, H.B.; Hampel, H.; Javadi, F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 2006, 4, 369-380. [CrossRef] [PubMed]
48. Berentzen, T.L.; Gamborg, M.; Holst, C.; Sorensen, T.I.; Baker, J.L. Body mass index in childhood and adult risk of primary liver cancer. J. Hepatol. 2014, 60, 325-330. [CrossRef] [PubMed]
49. Atabek, M.E.; Selver Eklioglu, B.; Akyurek, N. Which metabolic syndrome criteria best predict non-alcoholic fatty liver disease in children? Eat. Weight Disord. 2014, 19, 495-501. [CrossRef] [PubMed]
50. Singh, G.K.; Vitola, B.E.; Holland, M.R.; Sekarski, T.; Patterson, B.W.; Magkos, F.; Klein, S. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 2013, 162, 1160-1168. [CrossRef] [PubMed]
51. Fintini, D.; Chinali, M.; Cafiero, G.; Esposito, C.; Giordano, U.; Turchetta, A.; Pescosolido, S.; Pongiglione, G.; Nobili, V. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 72-74. [CrossRef] [PubMed]
52. Pacifico, L.; Di Martino, M.; de Merulis, A.; Bezzi, M.; Osborn, J.F.; Catalano, C.; Chiesa, C. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014, 59, 461-470. [CrossRef] [PubMed]
53. Nobili, V.; Alkhouri, N.; Bartuli, A.; Manco, M.; Lopez, R.; Alisi, A.; Feldstein, A.E. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr. Res. 2010, 67, 665-670. [CrossRef] [PubMed]
54. Pacifico, L.; Bonci, E.; Andreoli, G.; Romaggioli, S.; Di Miscio, R.; Lombardo, C.V.; Chiesa, C. Association of serum triglyceride-to-HDL cholesterol ratio with carotid artery intima-media thickness, insulin resistance and nonalcoholic fatty liver disease in children and adolescents. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 737-743. [CrossRef] [PubMed]
55. Nobili, V.; Donati, B.; Panera, N.; Vongsakulyanon, A.; Alisi, A.; Dallapiccola, B.; Valenti, L. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 632-636. [CrossRef] [PubMed]
56. Yuan, J.; Baker, S.S.; Liu, W.; Alkhouri, R.; Baker, R.D.; Xie, J.; Ji, G.; Zhu, L. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J. Gastroenterol. Hepatol. 2014, 29, 1292-1298. [CrossRef] [PubMed]
57. Choi, S.S.; Diehl, A.M. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr. Opin. Lipidol. 2008, 19, 295-300. [CrossRef] [PubMed]
58. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45, 1366-1374. [CrossRef] [PubMed]
59. Wanless, I.R.; Shiota, K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: A four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin. Liver Dis. 2004, 24, 99-106. [PubMed]
60. Morandi, A.; Maffeis, C. Predictors of metabolic risk in childhood obesity. Horm. Res. Paediatr. 2014, 82, 3-11. [CrossRef] [PubMed]
61. Torun, E.; Ozgen, I.T.; Gokce, S.; Aydin, S.; Cesur, Y. Thyroid hormone levels in obese children and adolescents with non-alcoholic fatty liver disease. J. Clin. Res. Pediatr. Endocrinol. 2014, 6, 34-39. [CrossRef] [PubMed]
62. Pacifico, L.; Bonci, E.; Ferraro, F.; Andreoli, G.; Bascetta, S.; Chiesa, C. Hepatic steatosis and thyroid function tests in overweight and obese children. Int. J. Endocrinol. 2013, 2013, 381014. [CrossRef] [PubMed]
63. De Vito, R.; Alisi, A.; Masotti, A.; Ceccarelli, S.; Panera, N.; Citti, A.; Salata, M.; Valenti, L.; Feldstein, A.E.; Nobili, V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int. J. Mol. Med. 2012, 30, 49-56. [PubMed]
64. Ferreyra Solari, N.E.; Inzaugarat, M.E.; Baz, P.; de Matteo, E.; Lezama, C.; Galoppo, M.; Galoppo, C.; Chernavsky, A.C. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J. Clin. Immunol. 2012, 32, 611-621. [CrossRef] [PubMed]
65. Barshop, N.J.; Sirlin, C.B.; Schwimmer, J.B.; Lavine, J.E. Review article: Epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008, 28, 13-24. [CrossRef] [PubMed]
66. Nobili, V.; Carpino, G.; Alisi, A.; Franchitto, A.; Alpini, G.; de Vito, R.; Onori, P.; Alvaro, D.; Gaudio, E. Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology 2012, 56, 2142-2153. [CrossRef] [PubMed]
67. Yoon, H.J.; Cha, B.S. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J. Hepatol. 2014, 6, 800-811. [CrossRef] [PubMed]
68. Swiderska-Syn, M.; Suzuki, A.; Guy, C.D.; Schwimmer, J.B.; Abdelmalek, M.F.; Lavine, J.E.; Diehl, A.M. Hedgehog pathway and pediatric nonalcoholic fatty liver disease. Hepatology 2013, 57, 1814-1825. [CrossRef] [PubMed]
69. Mouralidarane, A.; Soeda, J.; Visconti-Pugmire, C.; Samuelsson, A.M.; Pombo, J.; Maragkoudaki, X.; Butt, A.; Saraswati, R.; Novelli, M.; Fusai, G. et al. Maternal obesity programs offspring nonalcoholic fatty liver disease by innate immune dysfunction in mice. Hepatology 2013, 58, 128-138. [CrossRef] [PubMed]
70. Stienstra, R.; Saudale, F.; Duval, C.; Keshtkar, S.; Groener, J.E.; van Rooijen, N.; Staels, B.; Kersten, S.; Muller, M. Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity. Hepatology 2010, 51, 511-522. [CrossRef] [PubMed]
71. Morgan, M.L.; Sigala, B.; Soeda, J.; Cordero, P.; Nguyen, V.; McKee, C.; Mouraliderane, A.; Vinciguerra, M.; Oben, J.A. Acetylcholine induces fibrogenic effects via M2/M3 acetylcholine receptors in non-alcoholic steatohepatitis and in primary human hepatic stellate cells. J. Gastroenterol. Hepatol. 2016, 31, 475-483. [CrossRef] [PubMed]
72. Sigala, B.; McKee, C.; Soeda, J.; Pazienza, V.; Morgan, M.; Lin, C.I.; Selden, C.; Vander Borght, S.; Mazzoccoli, G.; Roskams, T. et al. Sympathetic nervous system catecholamines and neuropeptide y neurotransmitters are upregulated in human nafld and modulate the fibrogenic function of hepatic stellate cells. PLoS ONE 2013, 8, e72928. [CrossRef] [PubMed]
73. Shang, X.R.; Song, J.Y.; Liu, F.H.; Ma, J.; Wang, H.J. Gwas-identified common variants with nonalcoholic fatty liver disease in Chinese children. J. Pediatr. Gastroenterol. Nutr. 2015, 60, 669-674. [CrossRef] [PubMed]
74. Schwimmer, J.B.; Celedon, M.A.; Lavine, J.E.; Salem, R.; Campbell, N.; Schork, N.J.; Shiehmorteza, M.; Yokoo, T.; Chavez, A.; Middleton, M.S. et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009, 136, 1585-1592. [CrossRef] [PubMed]
75. Deboer, M.D.; Wiener, R.C.; Barnes, B.H.; Gurka, M.J. Ethnic differences in the link between insulin resistance and elevated ALT. Pediatrics 2013, 132, e718-e726. [CrossRef] [PubMed]
76. Lin, Y.C.; Chang, P.F.; Chang, M.H.; Ni, Y.H. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am. J. Clin. Nutr. 2014, 99, 869-874. [CrossRef] [PubMed]
77. Hernaez, R.; McLean, J.; Lazo, M.; Brancati, F.L.; Hirschhorn, J.N.; Borecki, I.B.; Harris, T.B.; Genetics of Obesity-Related Liver Disease (GOLD) Consortium; Nguyen, T.; Kamel, I.R.; et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third national health and nutrition examination survey. Clin. Gastroenterol. Hepatol. 2013, 11, 1183-1190. [CrossRef] [PubMed]
78. Romeo, S.; Kozlitina, J.; Xing, C.; Pertsemlidis, A.; Cox, D.; Pennacchio, L.A.; Boerwinkle, E.; Cohen, J.C.; Hobbs, H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40, 1461-1465. [CrossRef] [PubMed]
79. Santoro, N.; Kursawe, R.; D’Adamo, E.; Dykas, D.J.; Zhang, C.K.; Bale, A.E.; Cali, A.M.; Narayan, D.; Shaw, M.M.; Pierpont, B. et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010, 52, 1281-1290. [CrossRef] [PubMed]
80. Mangge, H.; Baumgartner, B.G.; Zelzer, S.; Pruller, F.; Schnedl, W.J.; Reininghaus, E.Z.; Haybaeck, J.; Lackner, C.; Stauber, R.; Aigner, E. et al. Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. Aliment. Pharmacol. Ther. 2015, 42, 99-105. [CrossRef] [PubMed]
81. Guan, L.; Shang, X.R.; Liu, F.H.; Song, J.Y.; Ma, J.; Wang, H.J. Association of INSIG2 rs9308762 with alt level independent of BMI. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 155-159. [CrossRef] [PubMed]
82. Rossi, F.; Bellini, G.; Alisi, A.; Alterio, A.; Maione, S.; Perrone, L.; Locatelli, F.; Miraglia del Giudice, E.; Nobili, V. Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PLoS ONE 2012, 7, e42259. [CrossRef] [PubMed]
83. Hyysalo, J.; Mannisto, V.T.; Zhou, Y.; Arola, J.; Karja, V.; Leivonen, M.; Juuti, A.; Jaser, N.; Lallukka, S.; Kakela, P. et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J. Hepatol. 2014, 60, 839-846. [CrossRef] [PubMed]
84. Qiao, A.; Liang, J.; Ke, Y.; Li, C.; Cui, Y.; Shen, L.; Zhang, H.; Cui, A.; Liu, X.; Liu, C. et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. Hepatology 2011, 54, 509-521. [CrossRef] [PubMed]
85. Weltman, M.D.; Farrell, G.C.; Hall, P.; Ingelman-Sundberg, M.; Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27, 128-133. [CrossRef] [PubMed]
86. Weltman, M.D.; Farrell, G.C.; Liddle, C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996, 111, 1645-1653. [CrossRef]
87. Sugimoto, Y.; Wakai, K.; Nakagawa, H.; Suma, S.; Sasakabe, T.; Sakamoto, T.; Takashima, N.; Suzuki, S.; Ogawa, S.; Ohnaka, K. et al. Associations between polymorphisms of interleukin-6 and related cytokine genes and serum liver damage markers: A cross-sectional study in the Japan Multi-Institutional Collaborative Cohort (J-MICC) study. Gene 2015, 557, 158-162. [CrossRef] [PubMed]
88. Lin, Y.C.; Chang, P.F.; Hu, F.C.; Chang, M.H.; Ni, Y.H. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics 2009, 124, e1221-e1227. [CrossRef] [PubMed]
89. Rossi, F.; Bellini, G.; Nobili, B.; Maione, S.; Perrone, L.; del Giudice, E.M. Association of the cannabinoid receptor 2 (Cb2) Gln63Arg polymorphism with indices of liver damage in obese children: An alternative way to highlight the CB2 hepatoprotective properties. Hepatology 2011, 54, 1102. [CrossRef] [PubMed]
90. Cordero, P.; Milagro, F.I.; Campion, J.; Martinez, J.A. Supplementation with methyl donors during lactation to high-fat-sucrose-fed dams protects offspring against liver fat accumulation when consuming an obesogenic diet. J. Dev. Orig. Health Dis. 2014, 5, 385-395. [CrossRef] [PubMed]
91. Cordero, P.; Milagro, F.I.; Campion, J.; Martinez, J.A. Maternal methyl donors supplementation during lactation prevents the hyperhomocysteinemia induced by a high-fat-sucrose intake by dams. Int. J. Mol. Sci. 2013, 14, 24422-24437. [CrossRef] [PubMed]
92. Mouralidarane, A.; Soeda, J.; Sugden, D.; Bocianowska, A.; Carter, R.; Ray, S.; Saraswati, R.; Cordero, P.; Novelli, M.; Fusai, G. et al. Maternal obesity programs offspring non-alcoholic fatty liver disease through disruption of 24-h rhythms in mice. Int. J. Obes. 2015, 39, 1339-1348. [CrossRef] [PubMed]
93. Cordero, P.; Li, J.; Oben, J.A. Epigenetics of obesity: Beyond the genome sequence. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 361-366. [CrossRef] [PubMed]
94. Cordero, P.; Li, J.; Temple, J.L.; Nguyen, V.; Oben, J.A. Epigenetic mechanisms of maternal obesity effects on the descendants. In Parental Obesity: Intergenerational Programming and Consequences; Green, L.R., Hester, R.L., Eds.; Springer-Verlag New York: New York, NY, USA, 2016.
95. Alisi, A.; Panera, N.; Agostoni, C.; Nobili, V. Intrauterine growth retardation and nonalcoholic fatty liver disease in children. Int. J. Endocrinol. 2011, 2011, 269853. [CrossRef] [PubMed]
96. Breij, L.M.; Kerkhof, G.F.; Hokken-Koelega, A.C. Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J. Clin. Endocrinol. Metab. 2014, 99, 1189-1195. [CrossRef] [PubMed]
97. Amarapurkar, D.; Kamani, P.; Patel, N.; Gupte, P.; Kumar, P.; Agal, S.; Baijal, R.; Lala, S.; Chaudhary, D.; Deshpande, A. Prevalence of non-alcoholic fatty liver disease: Population based study. Ann. Hepatol. 2007, 6, 161-163. [PubMed]
98. Hanada, S.; Snider, N.T.; Brunt, E.M.; Hollenberg, P.F.; Omary, M.B. Gender dimorphic formation of mouse mallory-denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010, 138, 1607-1617. [CrossRef] [PubMed]
99. Kozlov, A.V.; Duvigneau, J.C.; Hyatt, T.C.; Raju, R.; Behling, T.; Hartl, R.T.; Staniek, K.; Miller, I.; Gregor, W.; Redl, H. et al. Effect of estrogen on mitochondrial function and intracellular stress markers in rat liver and kidney following trauma-hemorrhagic shock and prolonged hypotension. Mol. Med. 2010, 16, 254-261. [CrossRef] [PubMed]
100. Yasuda, M.; Shimizu, I.; Shiba, M.; Ito, S. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999, 29, 719-727. [CrossRef] [PubMed]
101. Goh, G.B.; Pagadala, M.R.; Dasarathy, J.; Unalp-Arida, A.; Pai, R.K.; Yerian, L.; Khiyami, A.; Sourianarayanane, A.; Sargent, R.; Hawkins, C. et al. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic fatty liver disease. Dig. Dis. Sci. 2015, 60, 1825-1831. [CrossRef] [PubMed]
102. Suzuki, A.; Abdelmalek, M.F.; Schwimmer, J.B.; Lavine, J.E.; Scheimann, A.O.; Unalp-Arida, A.; Yates, K.P.; Sanyal, A.J.; Guy, C.D.; Diehl, A.M. et al. Association between puberty and features of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2012, 10, 786-794. [CrossRef] [PubMed]
103. Rangwala, F.; Guy, C.D.; Lu, J.; Suzuki, A.; Burchette, J.L.; Abdelmalek, M.F.; Chen, W.; Diehl, A.M. Increased production of sonic hedgehog by ballooned hepatocytes. J. Pathol. 2011, 224, 401-410. [CrossRef] [PubMed]
104. Li, T.; Leng, X.S.; Zhu, J.Y.; Wang, G. Suppression of hedgehog signaling regulates hepatic stellate cell activation and collagen secretion. Int. J. Clin. Exp. Pathol. 2015, 8, 14574-14579. [PubMed]
105. Hernaez, R.; Yeung, E.; Clark, J.M.; Kowdley, K.V.; Brancati, F.L.; Kao, W.H. Hemochromatosis gene and nonalcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 2011, 55, 1079-1085. [CrossRef] [PubMed]
106. Wu, S.; Tu, R.; Liu, G.; Huang, L.; Guan, Y.; Zheng, E. Focal fatty sparing usually does not arise in preexisting nonalcoholic diffuse homogeneous fatty liver. J. Ultrasound Med. 2014, 33, 1447-1452. [CrossRef] [PubMed]
107. Bellentani, S.; Saccoccio, G.; Masutti, F.; Croce, L.S.; Brandi, G.; Sasso, F.; Cristanini, G.; Tiribelli, C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132, 112-117. [CrossRef] [PubMed]
108. Patton, H.M.; Lavine, J.E.; van Natta, M.L.; Schwimmer, J.B.; Kleiner, D.; Molleston, J.; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008, 135, 1961-1971. [CrossRef] [PubMed]
109. Fracanzani, A.L.; Valenti, L.; Bugianesi, E.; Andreoletti, M.; Colli, A.; Vanni, E.; Bertelli, C.; Fatta, E.; Bignamini, D.; Marchesini, G. et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology 2008, 48, 792-798. [CrossRef] [PubMed]
110. Mofrad, P.; Contos, M.J.; Haque, M.; Sargeant, C.; Fisher, R.A.; Luketic, V.A.; Sterling, R.K.; Shiffman, M.L.; Stravitz, R.T.; Sanyal, A.J. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37, 1286-1292. [CrossRef] [PubMed]
111. Vernon, G.; Baranova, A.; Younossi, Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34, 274-285. [CrossRef] [PubMed]
112. Wilson, H.K.; Monster, A.C. New technologies in the use of exhaled breath analysis for biological monitoring. Occup. Environ. Med. 1999, 56, 753-757. [CrossRef] [PubMed]
113. Feldstein, A.E.; Alkhouri, N.; de Vito, R.; Alisi, A.; Lopez, R.; Nobili, V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am. J. Gastroenterol. 2013, 108, 1526-1531. [CrossRef] [PubMed]
114. Wieckowska, A.; Zein, N.N.; Yerian, L.M.; Lopez, A.R.; McCullough, A.J.; Feldstein, A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006, 44, 27-33. [CrossRef] [PubMed]
115. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011, 43, 617-649. [CrossRef] [PubMed]
116. Puri, K.; Nobili, V.; Melville, K.; Corte, C.D.; Sartorelli, M.R.; Lopez, R.; Feldstein, A.E.; Alkhouri, N. Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2013, 57, 114-118. [CrossRef] [PubMed]
117. Eng, K.; Lopez, R.; Liccardo, D.; Nobili, V.; Alkhouri, N. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Dig. Liver Dis. 2014, 46, 1008-1013. [CrossRef] [PubMed]
118. Oresic, M.; Hyotylainen, T.; Kotronen, A.; Gopalacharyulu, P.; Nygren, H.; Arola, J.; Castillo, S.; Mattila, I.; Hakkarainen, A.; Borra, R.J. et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013, 56, 2266-2274. [CrossRef] [PubMed]
119. Yilmaz, Y.; Ergelen, R.; Akin, H.; Imeryuz, N. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1330-1334. [CrossRef] [PubMed]
120. Schwimmer, J.B.; Middleton, M.S.; Behling, C.; Newton, K.P.; Awai, H.I.; Paiz, M.N.; Lam, J.; Hooker, J.C.; Hamilton, G.; Fontanesi, J. et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology 2015, 61, 1887-1895. [CrossRef] [PubMed]
121. Tovo, C.V.; de Mattos, A.Z.; Coral, G.P.; Branco, F.S.; Suwa, E.; de Mattos, A.A. Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphy. World J. Gastroenterol. 2015, 21, 4432-4439. [PubMed]
122. Kim, K.M.; Choi, W.B.; Park, S.H.; Yu, E.; Lee, S.G.; Lim, Y.S.; Lee, H.C.; Chung, Y.H.; Lee, Y.S.; Suh, D.J. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: A prospective study of living related potential liver donors. J. Gastroenterol. 2007, 42, 382-388. [CrossRef] [PubMed]
123. Nobili, V.; Vizzutti, F.; Arena, U.; Abraldes, J.G.; Marra, F.; Pietrobattista, A.; Fruhwirth, R.; Marcellini, M.; Pinzani, M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008, 48, 442-448. [CrossRef] [PubMed]
124. Ovchinsky, N.; Moreira, R.K.; Lefkowitch, J.H.; Lavine, J.E. Liver biopsy in modern clinical practice: A pediatric point-of-view. Adv. Anat. Pathol. 2012, 19, 250-262. [CrossRef] [PubMed]
125. Schwimmer, J.B.; Behling, C.; Newbury, R.; Deutsch, R.; Nievergelt, C.; Schork, N.J.; Lavine, J.E. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005, 42, 641-649. [CrossRef] [PubMed]
126. Mansoor, S.; Collyer, E.; Alkhouri, N. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic fatty liver disease. Curr. Gastroenterol. Rep. 2015, 17, 23. [CrossRef] [PubMed]
127. Nobili, V.; Parkes, J.; Bottazzo, G.; Marcellini, M.; Cross, R.; Newman, D.; Vizzutti, F.; Pinzani, M.; Rosenberg, W.M. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009, 136, 160-167. [CrossRef] [PubMed]
128. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52, 79-104. [CrossRef] [PubMed]
129. Nobili, V.; Marcellini, M.; Devito, R.; Ciampalini, P.; Piemonte, F.; Comparcola, D.; Sartorelli, M.R.; Angulo, P. Nafld in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44, 458-465. [CrossRef] [PubMed]
130. DeVore, S.; Kohli, R.; Lake, K.; Nicholas, L.; Dietrich, K.; Balistreri, W.F.; Xanthakos, S.A. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD. J. Pediatr. Gastroenterol. Nutr. 2013, 57, 119-123. [CrossRef] [PubMed]
131. Nobili, V.; Manco, M.; Devito, R.; Di Ciommo, V.; Comparcola, D.; Sartorelli, M.R.; Piemonte, F.; Marcellini, M.; Angulo, P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008, 48, 119-128. [CrossRef] [PubMed]
132. Oddy, W.H.; Herbison, C.E.; Jacoby, P.; Ambrosini, G.L.; O’Sullivan, T.A.; Ayonrinde, O.T.; Olynyk, J.K.; Black, L.J.; Beilin, L.J.; Mori, T.A. et al. The western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am. J. Gastroenterol. 2013, 108, 778-785. [CrossRef] [PubMed]
133. Nobili, V.; Manco, M.; Devito, R.; Ciampalini, P.; Piemonte, F.; Marcellini, M. Effect of Vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2006, 24, 1553-1561. [CrossRef] [PubMed]
134. Gronbaek, H.; Lange, A.; Birkebaek, N.H.; Holland-Fischer, P.; Solvig, J.; Horlyck, A.; Kristensen, K.; Rittig, S.; Vilstrup, H. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J. Pediatr. Gastroenterol. Nutr. 2012, 54, 223-228. [CrossRef] [PubMed]
135. Zelber-Sagi, S.; Nitzan-Kaluski, D.; Goldsmith, R.; Webb, M.; Zvibel, I.; Goldiner, I.; Blendis, L.; Halpern, Z.; Oren, R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. Hepatology 2008, 48, 1791-1798. [CrossRef] [PubMed]
136. Barlow, S.E.; Expert, C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: Summary report. Pediatrics 2007, 120, S164-S192. [CrossRef] [PubMed]
137. Haukeland, J.W.; Konopski, Z.; Eggesbo, H.B.; von Volkmann, H.L.; Raschpichler, G.; Bjoro, K.; Haaland, T.; Loberg, E.M.; Birkeland, K. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand. J. Gastroenterol. 2009, 44, 853-860. [CrossRef] [PubMed]
138. Krasnoff, J.B.; Painter, P.L.; Wallace, J.P.; Bass, N.M.; Merriman, R.B. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2008, 47, 1158-1166. [CrossRef] [PubMed]
139. Kistler, K.D.; Brunt, E.M.; Clark, J.M.; Diehl, A.M.; Sallis, J.F.; Schwimmer, J.B.; Group, N.C.R. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2011, 106, 460-468. [CrossRef] [PubMed]
140. Niblett, P. Statistics on Obesity, Physical Activity and Diet—England, 2015. Available online: http://www. hscic.gov.uk/catalogue/PUB16988 (accessed on 14 June 2016).
141. Jin, R.; Le, N.A.; Liu, S.; Farkas Epperson, M.; Ziegler, T.R.; Welsh, J.A.; Jones, D.P.; McClain, C.J.; Vos, M.B. Children with nafld are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J. Clin. Endocrinol. Metab. 2012, 97, E1088-E1098. [CrossRef] [PubMed]
142. O’Sullivan, T.A.; Oddy, W.H.; Bremner, A.P.; Sherriff, J.L.; Ayonrinde, O.T.; Olynyk, J.K.; Beilin, L.J.; Mori, T.A.; Adams, L.A. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J. Pediatr. Gastroenterol. Nutr. 2014, 58, 624-631. [CrossRef] [PubMed]
143. Spruss, A.; Bergheim, I. Dietary fructose and intestinal barrier: Potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J. Nutr. Biochem. 2009, 20, 657-662. [CrossRef] [PubMed]
144. Kawasaki, T.; Igarashi, K.; Koeda, T.; Sugimoto, K.; Nakagawa, K.; Hayashi, S.; Yamaji, R.; Inui, H.; Fukusato, T.; Yamanouchi, T. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J. Nutr. 2009, 139, 2067-2071. [CrossRef] [PubMed]
145. Kar, S.; Khandelwal, B. Fast foods and physical inactivity are risk factors for obesity and hypertension among adolescent school children in east district of sikkim, india. J. Nat. Sci. Biol. Med. 2015, 6, 356-359. [CrossRef] [PubMed]
146. Black, L.J.; Jacoby, P.; Ping-Delfos, S.; Chan, W.; Mori, T.A.; Beilin, L.J.; Olynyk, J.K.; Ayonrinde, O.T.; Huang, R.C.; Holt, P.G. et al. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J. Gastroenterol. Hepatol. 2014, 29, 1215-1222. [CrossRef] [PubMed]
147. Nobili, V.; Giorgio, V.; Liccardo, D.; Bedogni, G.; Morino, G.; Alisi, A.; Cianfarani, S. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur. J. Endocrinol. 2014, 170, 547-553. [CrossRef] [PubMed]
148. Li, J.; Cordero, P.; Nguyen, V.; Oben, J.A. The role of vitamins in the pathogenesis of non-alcoholic fatty liver disease. Integr. Med. Insights 2016, 11, 19-25. [CrossRef] [PubMed]
149. Roth, C.L.; Elfers, C.T.; Figlewicz, D.P.; Melhorn, S.J.; Morton, G.J.; Hoofnagle, A.; Yeh, M.M.; Nelson, J.E.; Kowdley, K.V. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 2012, 55, 1103-1111. [CrossRef] [PubMed]
150. George, P.S.; Pearson, E.R.; Witham, M.D. Effect of Vitamin D supplementation on glycaemic control and insulin resistance: A systematic review and meta-analysis. Diabet. Med. 2012, 29, e142-e150. [CrossRef] [PubMed]
151. Flachs, P.; Rossmeisl, M.; Bryhn, M.; Kopecky, J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin. Sci. 2009, 116, 1-16. [CrossRef] [PubMed]
152. Masterton, G.S.; Plevris, J.N.; Hayes, P.C. Review article: ω-3 fatty acids—A promising novel therapy for non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2010, 31, 679-692. [CrossRef] [PubMed]
153. Janczyk, W.; Socha, P.; Lebensztejn, D.; Wierzbicka, A.; Mazur, A.; Neuhoff-Murawska, J.; Matusik, P. ω-3 fatty acids for treatment of non-alcoholic fatty liver disease: Design and rationale of randomized controlled trial. BMC Pediatr. 2013, 13, 85. [CrossRef] [PubMed]
154. Nobili, V.; Carpino, G.; Alisi, A.; de Vito, R.; Franchitto, A.; Alpini, G.; Onori, P.; Gaudio, E. Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS ONE 2014, 9, e88005. [CrossRef] [PubMed]
155. Nobili, V.; Bedogni, G.; Alisi, A.; Pietrobattista, A.; Rise, P.; Galli, C.; Agostoni, C. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Arch. Dis. Child. 2011, 96, 350-353. [CrossRef] [PubMed]
156. Nobili, V.; Alkhouri, N.; Alisi, A.; Della Corte, C.; Fitzpatrick, E.; Raponi, M.; Dhawan, A. Nonalcoholic fatty liver disease: A challenge for pediatricians. JAMA Pediatr. 2015, 169, 170-176. [CrossRef] [PubMed]
157. Loy, J.J.; Youn, H.A.; Schwack, B.; Kurian, M.; Ren Fielding, C.; Fielding, G.A. Improvement in nonalcoholic fatty liver disease and metabolic syndrome in adolescents undergoing bariatric surgery. Surg. Obes. Relat. Dis. 2015, 11, 442-449. [CrossRef] [PubMed]
158. Peterli, R.; Steinert, R.E.; Woelnerhanssen, B.; Peters, T.; Christoffel-Courtin, C.; Gass, M.; Kern, B.; von Fluee, M.; Beglinger, C. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: A randomized, prospective trial. Obes. Surg. 2012, 22, 740-748. [CrossRef] [PubMed]
159. Sasaki, A.; Nitta, H.; Otsuka, K.; Umemura, A.; Baba, S.; Obuchi, T.; Wakabayashi, G. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front. Endocrinol. 2014, 5, 164. [CrossRef] [PubMed]
160. Chavez-Tapia, N.C.; Tellez-Avila, F.I.; Barrientos-Gutierrez, T.; Mendez-Sanchez, N.; Lizardi-Cervera, J.; Uribe, M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst. Rev. 2010, 1. [CrossRef]
161. Lassailly, G.; Caiazzo, R.; Buob, D.; Pigeyre, M.; Verkindt, H.; Labreuche, J.; Raverdy, V.; Leteurtre, E.; Dharancy, S.; Louvet, A. et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015, 149, 379-388. [CrossRef] [PubMed]
162. Nanda, K. Non-alcoholic steatohepatitis in children. Pediatr. Transpl. 2004, 8, 613-618. [CrossRef] [PubMed]
163. Schwimmer, J.B.; Middleton, M.S.; Deutsch, R.; Lavine, J.E. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2005, 21, 871-879. [CrossRef] [PubMed]
164. Lavine, J.E.; Schwimmer, J.B.; van Natta, M.L.; Molleston, J.P.; Murray, K.F.; Rosenthal, P.; Abrams, S.H.; Scheimann, A.O.; Sanyal, A.J.; Chalasani, N. et al. Effect of Vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The tonic randomized controlled trial. JAMA 2011, 305, 1659-1668. [CrossRef] [PubMed]
165. Belfort, R.; Harrison, S.A.; Brown, K.; Darland, C.; Finch, J.; Hardies, J.; Balas, B.; Gastaldelli, A.; Tio, F.; Pulcini, J. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355, 2297-2307. [CrossRef] [PubMed]
166. Sanyal, A.J.; Chalasani, N.; Kowdley, K.V.; McCullough, A.; Diehl, A.M.; Bass, N.M.; Neuschwander-Tetri, B.A.; Lavine, J.E.; Tonascia, J.; Unalp, A. et al. Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362, 1675-1685. [CrossRef] [PubMed]
167. Lee, J.; Hong, S.W.; Rhee, E.J.; Lee, W.Y. GLP-1 receptor agonist and non-alcoholic fatty liver disease. Diabetes Metab. J. 2012, 36, 262-267. [CrossRef] [PubMed]
168. Duvnjak, M.; Tomasic, V.; Gomercic, M.; Smircic Duvnjak, L.; Barsic, N.; Lerotic, I. Therapy of nonalcoholic fatty liver disease: Current status. J. Physiol. Pharmacol. 2009, 60, 57-66. [PubMed]
169. Tilg, H.; Moschen, A. Update on nonalcoholic fatty liver disease: Genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13, 391-396. [CrossRef] [PubMed]
170. Georgescu, E.F. Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? Adv. Ther. 2008, 25, 1141-1174. [CrossRef] [PubMed]
171. Carter, R.; Mouralidarane, A.; Ray, S.; Soeda, J.; Oben, J. Recent advancements in drug treatment of obesity. Clin. Med. 2012, 12, 456-460. [CrossRef]
172. Harrison, S.A.; Fecht, W.; Brunt, E.M.; Neuschwander-Tetri, B.A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009, 49, 80-86. [CrossRef] [PubMed]
173. Wierzbicki, A.S.; Oben, J. Nonalcoholic fatty liver disease and lipids. Curr. Opin. Lipidol. 2012, 23, 345-352. [CrossRef] [PubMed]
174. Tziomalos, K.; Athyros, V.G.; Paschos, P.; Karagiannis, A. Nonalcoholic fatty liver disease and statins. Metabolism 2015, 64, 1215-1223. [CrossRef] [PubMed]
175. Desai, S.; Baker, S.S.; Liu, W.; Moya, D.A.; Browne, R.W.; Mastrandrea, L.; Baker, R.D.; Zhu, L. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int. 2014, 34, 110-117. [CrossRef] [PubMed]
176. Li, Z.; Berk, M.; McIntyre, T.M.; Gores, G.J.; Feldstein, A.E. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 2008, 47, 1495-1503. [CrossRef] [PubMed]
177. Koliaki, C.; Szendroedi, J.; Kaul, K.; Jelenik, T.; Nowotny, P.; Jankowiak, F.; Herder, C.; Carstensen, M.; Krausch, M.; Knoefel, W.T. et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015, 21, 739-746. [CrossRef] [PubMed]
178. Guo, H.; Zhong, R.; Liu, Y.; Jiang, X.; Tang, X.; Li, Z.; Xia, M.; Ling, W. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition 2014, 30, 198-203. [CrossRef] [PubMed]
179. Ji, H.F.; Sun, Y.; Shen, L. Effect of Vitamin E supplementation on aminotransferase levels in patients with nafld, nash, and chc: Results from a meta-analysis. Nutrition 2014, 30, 986-991. [CrossRef] [PubMed]
180. Bjelakovic, G.; Nikolova, D.; Gluud, C. Antioxidant supplements and mortality. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 40-44. [CrossRef] [PubMed]
181. Ratziu, V. Treatment of NASH with ursodeoxycholic acid: Pro. Clin. Res. Hepatol. Gastroenterol. 2012, 36, S41-S45. [CrossRef]
182. Xiang, Z.; Chen, Y.P.; Ma, K.F.; Ye, Y.F.; Zheng, L.; Yang, Y.D.; Li, Y.M.; Jin, X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: A systematic review. BMC Gastroenterol. 2013, 13, 140. [CrossRef] [PubMed]
183. Pietu, F.; Guillaud, O.; Walter, T.; Vallin, M.; Hervieu, V.; Scoazec, J.Y.; Dumortier, J. Ursodeoxycholic acid with Vitamin E in patients with nonalcoholic steatohepatitis: Long-term results. Clin. Res. Hepatol. Gastroenterol. 2012, 36, 146-155. [CrossRef] [PubMed]
184. Vajro, P.; Franzese, A.; Valerio, G.; Iannucci, M.P.; Aragione, N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J. Pediatr. 2000, 136, 739-743. [CrossRef]
185. Van de Meeberg, P.C.; Houwen, R.H.; Sinaasappel, M.; Heijerman, H.G.; Bijleveld, C.M.; Vanberge-Henegouwen, G.P. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand. J. Gastroenterol. 1997, 32, 369-373. [CrossRef] [PubMed]
186. Dufour, J.F.; Oneta, C.M.; Gonvers, J.J.; Bihl, F.; Cerny, A.; Cereda, J.M.; Zala, J.F.; Helbling, B.; Steuerwald, M.; Zimmermann, A. et al. Randomized placebo-controlled trial of ursodeoxycholic acid with Vitamin E in nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2006, 4, 1537-1543. [CrossRef] [PubMed]
187. Loguercio, C.; Federico, A.; Tuccillo, C.; Terracciano, F.; D’Auria, M.V.; de Simone, C.; del Vecchio Blanco, C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 2005, 39, 540-543. [PubMed]
188. Vajro, P.; Mandato, C.; Licenziati, M.R.; Franzese, A.; Vitale, D.F.; Lenta, S.; Caropreso, M.; Vallone, G.; Meli, R. Effects of lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 2011, 52, 740-743. [CrossRef] [PubMed]
189. Machado, M.V.; Cortez-Pinto, H. Diet, microbiota, obesity, and NAFLD: A dangerous quartet. Int. J. Mol. Sci. 2016, 17. [CrossRef] [PubMed]
190. Fuchs, M. Non-alcoholic fatty liver disease: The bile acid-activated farnesoid x receptor as an emerging treatment target. J. Lipids 2012, 2012, 934396. [CrossRef] [PubMed]